Decoration of Burkholderia Hcp1 protein to virus-like particles as a vaccine delivery platform.
N. Khakhum, N. Baruch-Torres, J. L. Stockton, I. G. Chapartegui-Gonzalez, A. J. Badten, A. Adam, T. Wang, A. Huerta-Saquero, W. Yin, A. G. Torres
Abstract
Virus-like particles (VLPs) are protein-based nanoparticles frequently used as carrier in conjugate vaccine platforms. VLPs have been used to display foreign antigens for vaccination and to deliver immunotherapeutic against diseases. Hemolysin-coregulated proteins 1 (Hcp1) is a protein component of the Burkholderia type 6 secretion system which participates in intracellular invasion and dissemination. This protein has been reported as a protective antigen and is used in multiple vaccine candidates with various platforms against melioidosis, a severe infectious disease caused by the intracellular pathogen B. pseudomallei. In this study, we used P22 VLPs as a surface platform for decoration with Hcp1 using chemical conjugation. C57BL/6 mice were intranasally immunized with three doses of either PBS, VLPs or conjugated Hcp1-VLPs. Immunization with Hcp1-VLPs formulation induced Hcp1-specific-IgG, IgG1, IgG2c and IgA antibody responses. Furthermore, the serum from Hcp1-VLPs immunized mice enhanced the bacterial uptake and opsonophagocytosis by macrophages in the presence of complement. This study demonstrated an alternative strategy to develop a VLPs-based vaccine platform against Burkholderia species.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Assessments of hepatitis B virus-like particles and Crm197 as carrier proteins in melioidosis glycoconjugate vaccines
M. Bayliss, G. Pergolizzi, … J. L. Prior·bioRxiv·Apr 8, 2020
- A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture
Kaniz Fatema, Joseph S. Snowden, … David J. Rowlands·International Journal of Biological MacromoleculesPeer-reviewed·Feb 15, 2025
- VelcroVax: a bolt-on vaccine platform technology improves antibody titres against a viral glycoprotein in mice
N. J. Stonehouse, N. J. Kingston, … D. J. Rowlands·bioRxiv·Apr 22, 2022
- Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies
L. D. W. King, D. Pulido, … S. J. Draper·bioRxiv·Jan 4, 2024
- Cell-free expression of Nipah virus transmembrane proteins for proteoliposome vaccine design
Vivian T. Hu, Shahrzad Ezzatpour, … Neha P. Kamat·ACS NanoPeer-reviewed·Jun 3, 2025
- Tunable Rigid Spikes on Virus-Like Porous Silica Enable Mechanistically Controlled Nanovaccine Platforms
Cui Pang, Jiajia Wang, … Wujun Xu·Journal of Controlled ReleasePeer-reviewed·Jul 4, 2026